Tumor necrosis factor α-mediated tumor regression by the in vivo transfer of genes into the artery that leads to tumors

Cancer Research

Volumn 58, Issue 24, 1998, Pages 5725-5730

  Mizuguchi, Hiroyuki ^a,d   Nakagawa, Tetsuhiko ^a   Toyosawa, Satoru ^a   Nakanishi, Mahito ^b   Imazu, Susumu ^a   Nakanishi, Tsuyoshi ^a   Tsutsumi, Yasuo ^a   Nakagawa, Shinsaku ^a   Hayakawa, Takao ^c   Ijuhin, Naokuni ^a   Mayumi, Tadanori ^a  

^a OSAKA UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL MODEL; ARTICLE; CANCER THERAPY; FEMORAL ARTERY; GENE THERAPY; GENE TRANSFER; IMMUNITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR REGRESSION; TUMOR VASCULARIZATION;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DRUG CARRIERS; FEMORAL ARTERY; GENE TRANSFER TECHNIQUES; LIPOSOMES; MICE; SARCOMA 180; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 17444368010     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Rosenberg, S. A. Immunotherapy of cancer using interleukin 2. Immunol. Today, 9: 58-62, 1988.
2. Siegel, J. P., and Puri, R. K. Interleukin-2 toxicity. J. Clin. Oncol., 9: 694-704, 1991.
3. Moritz, T., Niederle, N., Baumann, J., May, D., Kurschel, E., Osieka, R., Kempeni, J., Schlick, E., and Schmidt, C. G. Phase I study of recombinant human tumor necrosis factor α in advanced malignant disease. Cancer Immunol. Immunother., 29; 144-150, 1989.
4. Hock, H., Dorsch, M., Richter, G., Kunnzendorf, U., Kruger-Krasagakes, S., Blankenstein, T., Qin, Z., and Diamantstein, T. Tumor-cell-targeted cytokine gene transfer in experimental models for cancer therapy. Nat. Immun., 13: 85-92, 1994.
5. Addison, C. L., Braciak, T., Ralston, R., Muller, W. J., Gauldie, J., and Graham, F. L. Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model. Proc. Natl. Acad. Sci. USA, 92; 8522-8526, 1995.
6. Cordier, L., Duffour, M. T., Sabourin, J. C., Lee, M. G., Cabannes, J., Ragot, T., Perricaudet, M., and Haddada, H. Complete recovery of mice from a pre-established tumor by direct intratumoral delivery of an adenovirus vector harboring the murine IL-2 gene. Gene Ther., 2; 16-21, 1995.
7. Elkins, K. L., Ennist, D. L., Winegar, R. K., and Weir, J. P. In vivo delivery of interleukin-4 by a recombinant vaccinia virus prevents tumor development in mice. Hum. Gene Ther., 5: 809-820, 1994.
8. Plautz, G. E., Yang, Z. Y., Wu, B. Y., Gao, X., Huang, L., and Nabel, G. J. Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc. Natl. Acad. Sci. USA, 90: 4645-4649, 1993.
9. Sun, W. H., Burkholder, J. K., Sun, J., Cuip, J., Turner, J., Lu, X. G., Pugh, T. D., Ereshler, W. B., and Yang, N-S. In vitro cytokine gene transfer by gene gun reduces tumor growth in mice. Proc. Natl. Acad. Sci. USA, 92: 2889-2893, 1995.
10. Nawroth, P. P., and Stern, D. M. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J. Exp. Med., 163: 740-745, 1986.
11. Shimomura, K., Manda, T., Mukumoto, S., Kobayashi, K., Nakano, K., and Mori, J. Recombinant human tumor necrosis factor-α: thrombus formation is a cause of anti-tumor activity. Int. J. Cancer, 41: 243-247, 1988.
12. Watanabe, N., Niitsu, Y., Umeno, H., Kuriyama, H., Neda, H., Yamauchi, N., Maeda, M., and Urushizaki, I. Toxic effect of tumor necrosis factor on tumor vasculature in mice. Cancer Res., 48: 2179-2183, 1988.
13. Renard, N., Lienard, D., Lespagnard, L., Eggermont, A., Heimann, R., and Lejeune, F. Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor α (rTNFα). Int. J. Cancer, 57: 656-663, 1994.